Agilent Technologies (A)

• Market cap: $38.6B
• 1 day: -1.04%
• 5 days: -1.18%
• 1 month: -11.27%
• 3 months: 2.51%
• 6 months: -3.30%
• Year to date: 1.45%
• 1 year: 0.03%
• 5 years: 59.13%
• 10 years: 224.39%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Employees: 17,900

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

50% more call options, than puts

Call options by funds: $163M | Put options by funds: $109M

37% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 87

2.28% more ownership

Funds ownership: 85.65% [Q3] → 87.93% (+2.28%) [Q4]

5% less repeat investments, than reductions

Existing positions increased: 351 | Existing positions reduced: 370

2% less funds holding

Funds holding: 1,033 [Q3] → 1,017 (-16) [Q4]

9% less capital invested

Capital invested by funds: $37B [Q3] → $33.7B (-$3.26B) [Q4]

42% less funds holding in top 10

Funds holding in top 10: 12 [Q3] → 7 (-5) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $142 5% upside
• Avg. target: $151 11% upside
• High target: $160 18% upside

6 analyst ratings

• positive: 2 33%
• neutral: 4 67%
• negative: 0 0%

Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target	7% upside $145	Equal-Weight Upgraded	10 Feb 2025
B of A Securities Derik De Bruin 45% 1-year accuracy 9 / 20 met price target	15% upside $156	Neutral Maintained	27 Jan 2025
Bernstein Eve Burstein 57% 1-year accuracy 4 / 7 met price target	7% upside $145	Market Perform Maintained	10 Jan 2025
Wells Fargo Brandon Couillard 14% 1-year accuracy 3 / 22 met price target	15% upside $155	Overweight Maintained	9 Dec 2024
Evercore ISI Group Vijay Kumar 53% 1-year accuracy 25 / 47 met price target	5% upside $142	In-Line Maintained	26 Nov 2024